Global Cancer Gene Therapy Market Poised for Remarkable Growth, Projected to Reach USD 3,142.2 Million by 2034 Driven by Personalized Medicine and Targeted Therapies | FMI

The global cancer gene therapy market is on the cusp of significant expansion, with sales expected to rise from USD 1,822.2 million in 2024 to a staggering USD 3,142.2 million by 2034. This impressive growth, marked by a compound annual growth rate (CAGR) of 5.6%, highlights the increasing demand for innovative cancer treatment solutions.

In 2023, the oncolytic virotherapy segment of cancer gene therapy alone generated USD 850.7 million in revenue, reflecting the growing recognition of this cutting-edge therapeutic approach. As healthcare providers and patients alike seek more effective options, the shift towards personalized medicine has become increasingly evident.

Access Key Market Insights: Request a Sample Report Now! https://www.futuremarketinsights.com/report-sample#5245502d47422d3134393731

Key Drivers of Market Growth:

The surge in personalized medicines and advancements in targeted therapies are pivotal to the growth of the cancer gene therapy market. Unlike traditional treatments such as chemotherapy and radiation—which often result in debilitating side effects due to their indiscriminate targeting of healthy cells—gene therapy offers a revolutionary solution. By directly addressing the genetic mutations that lead to tumor growth, this innovative treatment provides a more precise and individualized approach, significantly enhancing patient outcomes while minimizing toxicity.

With millions of new cancer cases diagnosed annually, the global cancer burden is escalating. This increasing prevalence, coupled with robust financial investments in gene therapy research, is expediting the progression of clinical trials across all phases, bringing novel therapies closer to regulatory approval. The result is a dynamic pipeline of innovative cancer gene therapies poised to offer hope to patients worldwide.

Investment in Research and Development:

The growth of the cancer gene therapy market is further supported by significant investments in research and development (R&D) from leading industry players. These financial commitments are vital for advancing clinical trials and securing quicker regulatory approvals. Collaborative efforts among companies are catalyzing the development of groundbreaking gene therapies, which are set to revolutionize cancer treatment.

As the landscape of cancer treatment evolves, the future is shifting toward highly targeted, personalized therapies that promise to enhance patient care substantially. The cancer gene therapy market is expected to remain a focal point for investors and pharmaceutical companies alike, driving forward innovative solutions to combat one of the world’s most formidable health challenges.

“The rising demand for personalized medicine, coupled with advancements in targeted therapies, is a key driver of the growth in the cancer gene therapy market,” said opines Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI).. “Gene therapy represents a paradigm shift in cancer treatment by specifically targeting genetic alterations that lead to cancer. Unlike traditional treatments that often affect healthy cells, gene therapy offers a more precise approach, which is expected to enhance treatment efficacy while minimizing side effects.”

Rising Demand for Market Data: Our Full Report Offers Deep Insights and Trend Analysis! https://www.futuremarketinsights.com/reports/cancer-gene-therapy-market

Here Are Some Key Takeaways From The Data:

The global cancer gene therapy market is expected to grow significantly in the coming years, driven by factors such as increasing prevalence of cancer, technological advancements, and rising awareness about gene therapy. The market is projected to reach a value of USD 3,142.2 million by 2034, with a CAGR of 5.6% during the forecast period.

• The global sales of cancer gene therapy are estimated to be worth USD 1,822.2 million in 2024.
• Sales are projected to rise at a CAGR of 5.6% over the forecast period between 2024 and 2034.
• China is expected to have the highest CAGR of 9.5% during the forecast period.
• Other countries with high CAGRs include South Korea (7.5%), Spain (5.5%), and France (4.8%).
• The United States and Canada are also expected to experience significant growth in the cancer gene therapy market.

Overall, the outlook for the cancer gene therapy market is very positive. The market is poised for significant growth in the coming years, as more and more patients benefit from this innovative treatment.

Competitive Landscape:

Significant investments in the cancer gene therapy market are increasingly directed toward collaboration and expansion as key strategies for growth and market consolidation. Companies are focusing on acquiring cutting-edge technologies and products to enhance their portfolios while forming strategic partnerships to expand their global reach.

Recent Developments in the Cancer Gene Therapy Market:

• In June 2021, Eisai and Bristol Myers Squibb entered into a collaboration to develop and commercialize Eisai’s antibody-drug conjugate (ADC), MORAb-202, for the treatment of advanced solid tumors.
• In June 2021, GSK partnered with iTeos Therapeutics to develop EOS-448, an anti-TIGIT monoclonal antibody, which had shown promise in phase 1 trials for advanced solid malignancies.

Key Players of Cancer Gene Therapy Industry:

• Merck KGaA
• Novartis AG
• AstraZeneca Plc.
• BIOCAD
• Crinetics Pharmaceuticals, Inc.
• EffRx Pharmaceuticals S.A.
• Euroscreen S.A.
• Vicore Pharma AB
• Amgen
• Bristol-Myers Squibb
• Cell Genesys Inc.
• Adaptimmune Therapeutics plc.
• Achieve Life Science Inc.
• BioCanCell Ltd.

Learn How Healthcare Markets Are Shifting – Download Our White Paper! https://www.futuremarketinsights.com/industry-analysis/therapy-area

Key Segments of Cancer Gene Therapy Industry

By Therapy:

In terms of therapy, the industry is divided into gene induced immunotherapy, oncolytic Virotherapy, gene transfer among others.

By Indication:

In terms of indication, the industry is segregated into breast cancer, ovarian cancer, liver cancer, pancreatic cancer, lung cancer, prostate cancer.

By Service Provider:

In terms of service provider, the industry is segregated into hospitals, clinical research laboratory, oncology institutes.

By Region:

Key countries of North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe and Middle East & Africa have been covered in the report.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube